| DC47707 |
CDK/HDAC-IN-1
|
CDK/HDAC-IN-1 shows remarkable CDK2/4/6 and HDAC6 inhibitory activity of IC50 = 60.9 ± 2.9, 276 ± 22.3, 27.2 ± 4.2, and 128.6 ± 0.4 nM, respectively. |
| DC47706 |
CDK2-IN-7
|
CDK2-IN-7 is a CDK2 inhibitor for treating cancer (IC50 < 50 nM). |
| DC47705 |
JH-XVI-178
|
JH-XVI-178 is a highly potent and selective inhibitor of CDK8/19 that displays low clearance and moderate oral pharmacokinetic properties. |
| DC47704 |
CDK9-IN-12
|
CDK9-IN-12 displays the optimal CDK9 inhibitory activity with an IC50 value of 5.41 nM. |
| DC47236 |
Cirtuvivint
|
Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research. |
| DC47205 |
Eltenac
|
Eltenac, a non-steroidal anti-inflammatory drug (NSAID), is a COX inhibitor. Eltenac shows IC50 of 0.03 μM for both COX-1 and COX-2 in isolated human whole blood. |
| DC47130 |
CDK5-IN-1
|
CDK5-IN-1, a potent CDK5 inhibitor, is against CDK5 activity less than 10 nM. CDK5-IN-1 is used for kidney diseases research. |
| DC47109 |
Cimpuciclib
|
Cimpuciclib is a cyclin-dependent kinase(CDK) inhibitor and antineoplastic. |
| DC47043 |
Ocarocoxib
|
Ocarocoxib, a potent COX-2 (cyclooxygenase-2) inhibitor, is a non-steroidal anti-inflammatory for veterinary use. |
| DC46945 |
Avotaciclib
|
Avotaciclib (BEY1107) is an orally active cyclin dependent kinase 1 (CDK1) inhibitor. Avotaciclib can be used for the research of cancer. |
